Our technology and the scientific premise it is founded on is relevant for several diseases, the company focus is currently on neurodegenerative diseases, where Alzheimer’s is first disease indication in the pipeline.
Pre ADx and Alzheimers’s disease
PreADx is a dynamic test that measures the ongoing catabolism of Abeta through the detection of split products from Abeta. The product is ready for use as a Research Use Product, and the product sheet can be downloaded here.
Alzheimer’s disease (AD) is a leading cause of dementia and poses a dramatic global health burden. More than 50 million people are currently living with dementia globally, with a projected increase to 152 million by 2050. The total worldwide cost of dementia is estimated to be US $1 trillion in 2019, and estimated to double by 20302. Although there are over 130 therapeutic candidates currently in pipeline, therapies under development have so far been failing. This in large part due to lack of understanding of the underlying disease mechanisms and the lack of optimal diagnostics tools that would enable for the necessary early diagnosis required for early intervention options.
Pre Diagnostics has a full pipeline of neurodegenerative diseases, where Parkinson’s Disease is the second diagnostic platform under development.